An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug

被引:116
作者
Bourdage, James S. [1 ]
Cook, Carolyn A. [1 ]
Farrington, Daphne L. [1 ]
Chain, Jana S. [1 ]
Konrad, Robert J. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
antibody assay; acid dissociation; immunogenicity; therapeutic proteins; ELISA; antigen interference;
D O I
10.1016/j.jim.2007.07.004
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Monoclonal antibody therapeutics typically have relatively long half-lives and can be dosed at high levels. Although formation of anti-drug antibodies (ADA) is relatively rare, detection of these antibodies can be very difficult in the presence of high circulating levels of drug. Typically these ADA are detected by bridging ELISAs which can be very sensitive to even low levels of drug. We describe an ELISA method based on affinity capture of ADA on solid-phase drug followed by removal of excess free drug, release and transfer of bound ADA and subsequent detection using biotinylated drug. The assay is both sensitive and highly tolerant to free drug with detection of 500 ng/ml of ADA readily achieved in the presence of 500 mu g/ml of drug. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 16 条
  • [1] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [2] Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
    Basser, RL
    O'Flaherty, E
    Green, M
    Edmonds, M
    Nichol, J
    Menchaca, DM
    Cohen, B
    Begley, CG
    [J]. BLOOD, 2002, 99 (07) : 2599 - 2602
  • [3] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
    Bendtzen, Klaus
    Geborek, Pierre
    Svenson, Morten
    Larsson, Lotta
    Kapetanovic, Meliha C.
    Saxne, Tore
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 3782 - 3789
  • [4] Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies
    Bourdage, JS
    Lee, TN
    Taylor, JM
    Willey, MB
    Brandt, JT
    Konrad, RJ
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (3-4) : 685 - 690
  • [5] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
    Casadevall, N
    Nataf, J
    Viron, B
    Kolta, A
    Kiladjian, J
    Martin-Dupont, P
    Michaud, P
    Papo, T
    Ugo, V
    Teyssandier, I
    Varet, B
    Mayeux, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) : 469 - 475
  • [6] DIAMANDIS EP, 1991, CLIN CHEM, V37, P625
  • [7] DIXON K, 1974, CLIN CHEM, V20, P1275
  • [8] Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-D33 monoclonal antibody HuM195
    Feldman, E
    Kalaycio, M
    Weiner, G
    Frankel, S
    Schulman, P
    Schwartzberg, L
    Jurcic, J
    Velez-Garcia, E
    Seiter, K
    Scheinberg, D
    Levitt, D
    Wedel, N
    [J]. LEUKEMIA, 2003, 17 (02) : 314 - 318
  • [9] Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin
    Fineberg, NS
    Fineberg, SE
    Anderson, JH
    Birkett, MA
    Gibson, RG
    Hufferd, S
    [J]. DIABETES, 1996, 45 (12) : 1750 - 1754
  • [10] DETERMINATION OF INSULIN-ANTIBODIES
    KANSAL, PC
    BANDISODE, MS
    BOSHELL, BR
    [J]. HORMONE AND METABOLIC RESEARCH, 1979, 11 (03) : 187 - 189